BIOGEN IDEC INC.

BIOGEN IDEC INC.

• Correction: FDA-Multiple Sclerosis Drug story

  In a story March 27 about a new multiple sclerosis drug, The Associated Press reported erroneously that Novartis' drug Gilenya was launched in March ... 

• Elan moves to deter takeover bid

  Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis ... 

• Royalty Pharma offers to buy Elan for about $6.5B

  Royalty Pharma said Monday that it wants to buy Elan Corp. PLC for about $6.5 billion, but has yet to receive a formal response from the Irish ... 

• Elan, Biogen change terms of Tysabri collaboration

  Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp. PLC in exchange for ... 

• 

  US stocks close mixed on uneven economic signals

  U.S. stocks meandered between small gains and losses Monday, cooling off after a rally that had pushed the Standard & Poor's 500 index above 1,500 for ...